MIDTERM MEETING OF THE EXANDAS RESEARCH PROGRAM PARTICIPANTS IN THE CONTEXT OF Η2020-MSCA-RISE 2015

12/06/2017|All articles, Horizon 2020, Research & development|

The first meeting of the research program under the distinct title “EXANDAS” of the Marie Sklodowska Curie Actions (MSCA) program successfully took place on 21-22 April 2017. The program aims to exploit the aromatic plants’ by-products, Chios Mastic included, for the purpose of developing novel pharmaceutical products. The program’s coordinator is Assistant Prof. N. Aligiannis, [...]

PRESS RELEASE FOR THE INITIATION OF A CLINICAL STUDY ON THE EFFECT OF CHIOS MASTIC ON BLOOD VESSELS’ FUNCTIONALITY AND INFLAMMATION

26/09/2016|All articles, Clinical studies, Research & development|

IASIS PHARMA proudly announces the exclusive sponsorship of a clinical trial on the effect of Chios Mastic on blood vessels’ functionality and inflammation”. The research center conducting the study is  “Alexandra” General Hospital, the results of the study are expected to be announced the last quarter of 2016.

PRESS RELEASE FOR THE INITIATION OF A CLINICAL STUDY ON THE EFFECT OF MASTIHATHERAPY CAPS ON HELICOBACTER PYLORI

26/09/2016|All articles, Clinical studies, Research & development|

IASIS PHARMA proudly announces the exclusive sponsorship of a clinical trial on the effect of Chios Mastic in capsules on Helicobacter Pylori. The main research center is “Laiko” Hospital of Athens. Read more about the study's latest findings here

More news soon

01/07/2016|All articles, Company news, Exploiting the gifts of Greek nature, Research and development projects|

KICK OFF MEETING OF THE ΕΧΑΝDAS PROGRAM

14/04/2016|All articles, Horizon 2020, Research & development|

ATHENS, 01-02/04/2016 The kick-off meeting of the research program under the distinct title   “EXANDAS” of the Marie Sklodowska Curie Actions (MSCA) programs was successfully organized on 1-2 April 2016. The specific program aims  to exploit the aromatic plants’ by-products such as the Chios Mastic for the purpose of developing novel pharmaceutical products. The meeting took place [...]

PARICIPATION IN THE HORIZON PROGRAM

18/11/2015|All articles, Horizon 2020, Research & development|

BRUSSELS, 10/11/2015 IASIS PHARMA proudly announces its participation in a program of H2020. The program Horizon 2020 is the financing framework of the EU for research and Innovation that will cover the period 2014-2020, with a budget of approximately 80 billion Euros. The program supports the strategy "Europe 2020" that promotes research and innovation as the [...]

Load More Posts